Deutsche Bank analyst George Hill lowered the firm’s price target on UnitedHealth (UNH) to $328 from $362 and keeps a Buy rating on the shares ahead of the Q2 report. The firm says investor sentiment on the shares “has deteriorated significantly” due to a series of negative headlines and industry headwinds. Deutsche reduced estimates ahead of the earnings report, saying Optum Health remains its biggest concern.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth Stock Collapse Continues: Here’s What This Investor Thinks Will Happen Next
- Who Is TipRanks’ All-Star Analyst on UnitedHealth Stock (UNH)?
- ACA marketplace plans seek double digit rate increases for 2026, WSJ says
- U.S. Health insurers prescription drug denials on the rise, NYT says
- Bernstein Calls UnitedHealth Stock (UNH) a Top Pick Ahead of Q2 Earnings